US EditionPublished • loading... • Updated
Trump Negotiating Deal With Ozempic Maker to Sell Some Weight-Loss Drugs for $149 via TrumpRx: Report
The Trump administration aims to reduce weight-loss drug prices to $149 monthly and expand Medicare coverage, improving affordability for beneficiaries, according to sources.
- This past week the Trump administration negotiated with Eli Lilly and Novo Nordisk to cut Zepbound and Wegovy prices to as low as $149 a month, people familiar with the talks said.
- President Donald Trump revived the drug‑pricing initiative via the May executive order, while list prices for Zepbound and Wegovy remain above $1,000, prompting lower‑cost cash options and retailer deals.
- Companies would agree to sell directly to consumers at below-list prices, but it remains unclear if private insurers or Medicare would cover reduced cash prices or which Medicare patients qualify.
- The deal could be announced as early as Thursday, with final pricing expected by Nov. 1 and new prices unveiled by Nov. 30, marking a key outcome of President Donald Trump’s drug‑pricing initiative.
- The White House spokesperson Kush Desai cautioned that discussions about unannounced deals should be regarded as speculation, as reported by Endpoint News.
Insights by Ground AI
17 Articles
17 Articles
Trump administration nears deals with pharmaceutical companies to offer obesity drugs for $149 a month
The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to consumers for as low as $149 per month, according to two people familiar with the negotiations.
·Atlanta, United States
Read Full Article
Coverage Details
Total News Sources17
Leaning Left6Leaning Right1Center8Last UpdatedBias Distribution53% Center
Bias Distribution
- 53% of the sources are Center
53% Center
L 40%
C 53%
Factuality
To view factuality data please Upgrade to Premium
